

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Hill et al. Examiner: Layno, Carl Hernandz

Serial No.: 10/768,999 Group Art Unit: 3766

Filing Date: 01/30/2004 Docket No.: P-9091.06

Title: METHOD AND SYSTEM FOR NERVE STIMULATION PRIOR TO AND DURING A

MEDICAL PROCEDURE

CERTIFICATE OF MAILING UNDER 37 CFR 1.8: I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this ______ day October, 2006.

Signature

Diane M. Anderson

Printed Name

TERMINAL DISCLAIMER UNDER 37 C.F.R. § 1.321(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Certificate Under 37 C.F.R. § 3.73(b)

Your petitioner, Medtronic, Inc., a corporation of the State of Minnesota having a place of business at 710 Medtronic Parkway, Minneapolis, Minnesota, certifies that it is the exclusive owner of the entire right, title and interest in and to the above-identified patent application (Serial No. 10/768,999), by virtue of an assignment recorded in the parent at R011182/F0696, on 09/26/2000, and in and to U.S. Patent Nos. 6,532,388; 6,718,208, by virtue of an assignment recorded at R011151/F0611, on 09/26/2000 and at R015569/F0532, on 09/26/2000.

10/05/2006 HDESTA1 00000030 132546 10768999

01 FC:1814 130.00 DA

Serial No. 10/768,999 Dkt.: P-9091.06

Filing Date: 01/30/2004

Title: METHOD AND SYSTEM FOR NERVE STIMULATION PRIOR TO AND DURING A MEDICAL

PROCEDURE

The undersigned (whose title is supplied below) is empowered to act on behalf of Petitioner.

Documents establishing the chain of title of the subject patent application (including the aforementioned assignment and a notice from the Patent and Trademark Office noting its recording location) have been reviewed and I certify that, to the best of my knowledge and belief, title is in Petitioner.

Terminal Disclaimer

Petitioner hereby disclaims, except as provided below, the terminal part of any patent granted on the above-identified patent application that would extend beyond the expiration date of a full statutory term as defined in 35 U.S.C. §154 to §156 and §173 of the above-identified patent, not shortened by terminal disclaimer. Petitioner hereby agrees that any patent granted on the above-identified patent application shall be enforceable only for and during such period that the legal title to such patent and U.S. Patent Nos. 6,532,388; 6,718,208 are commonly owned. This agreement is to run with any patent granted on the above-identified patent application and to be binding upon the grantee, its successors and assigns.

Limitations on the Disclaimer

In making the above disclaimer, Petitioner does not disclaim any terminal part of any patent granted on the above-identified patent application prior to the expiration date of the full statutory term, not shortened by terminal disclaimer, of U.S. Patent Nos. 6,532,388; 6,718,208, if any or all such patents: (1) expires for failure to pay a maintenance fee; (2) is held unenforceable or are found invalid by a court of competent jurisdiction; (3) is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321; (4) has all claims canceled by a reexamination certificate; (5) is reissued; or (6) is otherwise terminated prior to the expiration of its full statutory term.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made herein on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the above-identified application or any patent issuing thereon.

TERMINAL DISCLAIMER

Dkt.: P-9091.06

Page 3

Serial No. 10/768,999

Filing Date: 01/30/2004 Title: METHOD ANI

METHOD AND SYSTEM FOR NERVE STIMULATION PRIOR TO AND DURING A MEDICAL

PROCEDURE

Please charge \$130.00 to Deposit Account No. 13-2546 for the fee required by 37 C.F.R. § 1.20(d). Please charge any additional required fees or credit any overpayment to Deposit Account No. 13-2546.

Date: /0/7 . 2006

Respectfully submitted,

Earle F. Kyle, IV

Vice President, Senior Counsel

Medtronic, Inc.

7611 Northland Drive

Minneapolis, MN 55428

Telephone: (763) 391-9280

Fax. (763) 391-9668